interesting valuation level: $520+ MM for a monitoring company without a product yet vs. the recent $600 MM for a insulin delivery company with fully devevloped product line (Animas), and demonstrable customer base. How many T2 patients will be willing to have an implantable?
I view the valuation issue from a different perspective. No disrespect to Animas and its products, but if it could attract a $600 MM offer from J&J, despite the fact that the worldwide insulin pump market is already dominated by 2 other major companies, it is conceivable to me that DXCM's market cap can continue to grow significantly. Continuous glucose monitoring is not a me too product category. It appears that Dexcom is on the lead with its technology with Abbott too. Industry consolidation could easily lead to Dexcom being acquired one day at a valuation level that many will find absurd. Just my opinion.